API | caplacizumab

caplacizumab (cablivi) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA First in Class Fast Track ^FDA

AACT ChEMBL Drugs@FDA MeSH

Active Ingredient History

NOW

Caplacizumab is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
caplacizumab

More Chemistry

Pharmacology

Mechanisms of Action:
- von Willebrand factor (Homo sapiens) ^UniProt
- von Willebrand factor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

alx-0081 | anti-vwf nanobody | caplacizumab | caplacizumab-yhdp

Organizations (4)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (2)

Purpura, Thrombocytopenic (approved 2019)

Purpura, Thrombotic Thrombocytopenic

Experimental Indications - Clinical Trial Phases 1-4 (6)

Angina Pectoris (Phase 2)

Angina, Unstable (Phase 2)

Healthy Volunteers (Phase 1)

Purpura (Phase 3)

Purpura, Thrombotic Thrombocytopenic (Phase 3)

ST Elevation Myocardial Infarction (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue